Toutes les études
AutoriséExploratoire thérapeutique (Phase II)Interventionnel

A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of SIR9900 in Patients with VEXAS Syndrome (SIVEX)

VEXAS syndrome is a rare condition that causes painful swelling, fatigue, and blood problems. Currently, most people manage it using steroids. While steroids help, taking high doses for a long time often causes difficult side effects. This trial, called SIVEX, is testing an experimental medicine called SIR9900. Researchers want to know if SIR9900 can calm down inflammation and improve blood counts, such as red blood cells and platelets. A key aim is to see if patients can lower their steroid dose to 10 mg a day or less without their illness getting worse. The study compares SIR9900 against a dummy treatment (a placebo). You would be in the trial for around a year, attending regular hospital visits for blood tests, heart checks, and symptom reviews to make sure you are safe.

En un coup d'œil

Statut
Autorisé
Phase
Exploratoire thérapeutique (Phase II)
Sponsor
Sironax USA Inc.
Objectif d'inscription
24
Démarrer
23 juil. 2026

De quoi parle cette étude ?

VEXAS syndrome is a recently discovered inflammatory condition. It happens because of a change in a gene within blood cells, leading the body's immune system to attack healthy tissues. People with VEXAS often face severe, recurring symptoms, including extreme tiredness, painful joints, skin rashes, lung problems, and low blood counts.

At the moment, the main treatment is high-dose steroid medication. Although steroids help keep inflammation under control, they do not cure the condition. Taking them over months or years can also cause serious health issues, such as weakened bones, weight gain, and higher infection risks. Doctors urgently need new treatments that target the disease directly so patients can rely less on steroids.

The SIVEX trial is investigating a new drug called SIR9900. Researchers want to see how well it works and check for any unwanted side effects. They will track whether it calms inflammation markers in the blood (such as CRP and ferritin) and helps the body make healthier blood cells. Most importantly, they want to see if it gives people more days free from painful flare-ups while cutting down their steroid use.

To make sure the results are fair and accurate, this is a double-blind trial. This means half the participants will receive SIR9900 and half will receive a dummy pill (placebo). Neither you nor your study doctors will know which one you are taking during the trial, but you will be monitored very closely throughout.

Points clés

  • The SIVEX trial tests a new drug called SIR9900 for adults with VEXAS syndrome.
  • A main goal is to help patients safely cut back on steroid medication without causing flare-ups.
  • The study lasts about 52 weeks and involves regular check-ups, blood tests, and heart monitoring.
  • Participants are randomly chosen to receive either the active medicine or a dummy tablet (placebo).
  • Joining is completely voluntary, and you can leave the study at any time.

Qui peut être éligible ?

This trial is open to adults aged 18 and older who have a confirmed diagnosis of VEXAS syndrome. Both men and women can take part.

Participants will generally be people who currently need steroid treatment to manage their symptoms, and whose doctors are looking to reduce their steroid dose safely. People with low red blood cells (anaemia) or low platelets linked to their condition may also be suitable.

You might not be eligible if you have certain other active infections, severe heart, liver, or kidney problems, or if you are taking specific medications that could clash with the study drug. Pregnant or breastfeeding women are usually not able to join for safety reasons. A full health screening will confirm if the trial is right for you.

Cet étude pourrait-elle vous convenir ?

Répondez à ces questions rapides pour voir si vous êtes éligible. Ceci est un guide uniquement — l'équipe de recherche prend la décision finale.

  1. I am aged 18 or older.
  2. I have been diagnosed with VEXAS syndrome.
  3. I am currently taking steroid medication to manage my symptoms.
  4. I am able and willing to attend regular hospital appointments for tests over 12 months.
  5. I am comfortable with the possibility of receiving either the trial drug or a placebo.
Répondez à chaque question pour voir votre résultat.

En quoi consiste la participation ?

Taking part in this study lasts for about 52 weeks (one year). During this time, you will take study tablets (either SIR9900 or a matching placebo) alongside your prescribed care. You will visit the clinic regularly for health checks, especially in the first few months. Visits will include physical examinations, blood tests, urine tests, and heart tracings (ECGs). The study doctors will carefully guide you through slowly lowering your daily steroid dose, watching closely to see how your body responds. If you ever experience a disease flare-up, the medical team will step in promptly to adjust your treatment and keep you comfortable.

Risques et avantages potentiels

Taking part may help improve your VEXAS symptoms and could allow you to lower your steroid dose, which may reduce long-term steroid side effects. You will also have very frequent, specialist health monitoring. However, there are potential risks. You might experience side effects from the new medicine, or you might receive the placebo, which contains no active drug. There is also a chance your symptoms could flare up as your steroid dose is lowered. Your safety comes first, and you are entirely free to leave the trial at any point without it affecting your usual NHS care.

Emplacements (1)

Certains emplacements de site sont approximatifs. Nous améliorons cela — veuillez vérifier avec l'équipe d'essai avant de vous déplacer.
  • —
    Non vérifié
    Italie

Questions fréquentes

What is a placebo and why is it used?

A placebo looks just like the real medicine but contains no active ingredients. Researchers use it to compare results fairly and prove whether any improvements are truly caused by SIR9900.

Will I have to stop taking my regular steroids?

No, you will not stop suddenly. The study team will work with you to see if your steroid dose can be slowly and safely reduced to 10 mg a day or less.

What happens if my symptoms get worse during the study?

The trial team will monitor you closely. If your disease flares up, doctors have clear medical plans in place to treat you immediately and adjust your medication.

Do I have to pay to take part?

No. The study medication and all trial tests are provided free of charge, and travel expenses to hospital visits are often reimbursed.

Puis-je quitter l'étude si je change d'avis ?

Yes. Taking part is completely voluntary. You can withdraw at any time, for any reason, and your regular medical care will continue as normal.

Comment en savoir plus

Parlez toujours à votre médecin généraliste ou spécialiste avant de décider de participer à une étude.

Discussion

Discussion communautaire

Propulsé par notre forum à community.patient.info. Veuillez être respectueux — ceci n'est pas un avis médical.